Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects [3 months] · Children with otitis media with effusion
1 finding from 1 review
Adverse effects: exposure keratopathy · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes adverse effects: exposure keratopathy compared with standard treatment alone (very low certainty).
1 finding from 1 review
Adverse effects [2 weeks to 6 months] · Children with otitis media with effusion
Summary of findings: oral steroids plus antibiotic showed no clear difference in adverse effects [2 weeks to 6 months] compared with control plus antibiotic (low certainty).
1 finding from 1 review
Adverse effects ‐ burning · people with atopic dermatitis
1 finding from 1 review
Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
B4: Discontinuation of therapy due to maternal adverse effects – an all women · the woman
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Adverse effects · patients undergoing cataract surgery
1 finding from 1 review
Adverse effects: leucopenia · SSNS in children
Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Complications (adverse effects) · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Intra-articular injection of sodium hyaluronate showed no clear difference in complications (adverse effects) compared with intra-articular injection of corticosteroids (betamethasone); GRADE not reported.
1 finding from 1 review
Adverse effects: ANCA positive/arthritis · SSNS in children
Levamisole showed no clear difference in adverse effects: ANCA positive/arthritis compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Nausea and vomiting · patients with acute asthma
ICS showed no clear difference in adverse effects ‐ nausea/vomiting compared with placebo (low certainty).
1 finding from 1 review
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 2.91 [1.6, 5.28]
1 study · 371 participants
Moderate
RR 4.59 [3.1, 6.78]
1 study · 377 participants
Moderate
RR 3.79 [2.99, 4.81]
1 study · 972 participants
Moderate
Maternal adverse effects of therapy · women at risk of preterm birth
Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).
1 finding from 1 review
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall adverse effects Duration of trials: 8 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 16 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 24 weeks (moderate certainty).
1 finding from 1 review